1. Home
  2. CYTK vs AG Comparison

CYTK vs AG Comparison

Compare CYTK & AG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CYTK
  • AG
  • Stock Information
  • Founded
  • CYTK 1997
  • AG 1979
  • Country
  • CYTK United States
  • AG Canada
  • Employees
  • CYTK N/A
  • AG N/A
  • Industry
  • CYTK Biotechnology: Pharmaceutical Preparations
  • AG Precious Metals
  • Sector
  • CYTK Health Care
  • AG Basic Materials
  • Exchange
  • CYTK Nasdaq
  • AG Nasdaq
  • Market Cap
  • CYTK 4.6B
  • AG 4.0B
  • IPO Year
  • CYTK 2004
  • AG N/A
  • Fundamental
  • Price
  • CYTK $59.89
  • AG $12.75
  • Analyst Decision
  • CYTK Buy
  • AG Strong Buy
  • Analyst Count
  • CYTK 16
  • AG 3
  • Target Price
  • CYTK $76.73
  • AG $11.08
  • AVG Volume (30 Days)
  • CYTK 2.5M
  • AG 25.5M
  • Earning Date
  • CYTK 11-05-2025
  • AG 11-06-2025
  • Dividend Yield
  • CYTK N/A
  • AG 0.16%
  • EPS Growth
  • CYTK N/A
  • AG N/A
  • EPS
  • CYTK N/A
  • AG 0.04
  • Revenue
  • CYTK $85,738,000.00
  • AG $826,595,000.00
  • Revenue This Year
  • CYTK $363.61
  • AG $91.40
  • Revenue Next Year
  • CYTK $64.08
  • AG N/A
  • P/E Ratio
  • CYTK N/A
  • AG $331.71
  • Revenue Growth
  • CYTK 2635.74
  • AG 61.34
  • 52 Week Low
  • CYTK $29.31
  • AG $5.09
  • 52 Week High
  • CYTK $61.19
  • AG $13.55
  • Technical
  • Relative Strength Index (RSI)
  • CYTK 75.04
  • AG 69.01
  • Support Level
  • CYTK $47.22
  • AG $11.61
  • Resistance Level
  • CYTK $50.78
  • AG $13.55
  • Average True Range (ATR)
  • CYTK 2.30
  • AG 0.73
  • MACD
  • CYTK 0.66
  • AG 0.06
  • Stochastic Oscillator
  • CYTK 90.55
  • AG 77.78

About CYTK Cytokinetics Incorporated

Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

About AG First Majestic Silver Corp. (Canada)

First Majestic Silver Corp is engaged in the production, development, exploration, and acquisition of mineral properties with a focus on silver and gold production in North America. It owns three producing mines in Mexico consisting of the San Dimas Silver/Gold Mine, the Santa Elena Silver/Gold Mine, and the La Encantada Silver Mine.

Share on Social Networks: